We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-13.06%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$1.87B
AUM Growth
-$516M
Cap. Flow
-$95.3M
Cap. Flow %
-5.09%
Top 10 Hldgs %
48.99%
Holding
144
New
7
Increased
8
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
SRRK icon
Scholar Rock
SRRK
+$45.3M
2
FATE icon
Fate Therapeutics
FATE
+$16.6M
3
CYTK icon
Cytokinetics
CYTK
+$11.1M
4
SNTI icon
Senti Biosciences Holdings
SNTI
+$4.46M
5
WVE icon
Wave Life Sciences
WVE
+$3.85M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$60.4M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$18.9M
3
SGEN
Seagen Inc. Common Stock
SGEN
+$18M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
5
BLU
BELLUS Health Inc.
BLU
+$12.3M

Sector Composition

Rank Sector Weight
1 Healthcare 89.44%
2 Consumer Discretionary 5.28%
3 Miscellaneous 3.96%
4 Financials 0.87%
5 Consumer Staples 0.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
51
Agenus
AGEN
$323M
$5.82M 0.31%
152,850
-127,375
-45% -$4.62M
AMAM
52
DELISTED
Ambrx Biopharma Inc
AMAM
$5.7M 0.3%
2,152,291
– –
ACHL
53
DELISTED
Achilles Therapeutics
ACHL
$5.68M 0.3%
2,255,375
– –
KRON
54
DELISTED
Kronos Bio
KRON
$5.62M 0.3%
1,542,954
– –
DSGN icon
55
Design Therapeutics
DSGN
$765M
$5.6M 0.3%
400,000
– –
OVID icon
56
Ovid Therapeutics
OVID
$527M
$5.38M 0.29%
2,500,000
– –
OTLY
57
Oatly Group
OTLY
$399M
$5.19M 0.28%
75,000
– –
SQZ
58
DELISTED
SQZ Biotechnologies Company
SQZ
$5.11M 0.27%
1,606,309
– –
ALPN
59
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.05M 0.27%
593,030
– –
MRNS
60
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.84M 0.26%
1,000,000
– –
CFRX
61
DELISTED
ContraFect Corporation
CFRX
$4.61M 0.25%
18,750
– –
CYPH
62
Cypherpunk Technologies Inc
CYPH
$238M
$4.6M 0.25%
400,000
– –
LYEL icon
63
Lyell Immunopharma
LYEL
$267M
$4.56M 0.24%
35,000
– –
BDTX icon
64
Black Diamond Therapeutics
BDTX
$114M
$4.05M 0.22%
1,646,517
– –
ALXO icon
65
ALX Oncology
ALXO
$261M
$4.04M 0.22%
500,000
– –
TSHA icon
66
Taysha Gene Therapies
TSHA
$1.65B
$3.87M 0.21%
1,040,882
– –
SYRS
67
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.85M 0.21%
400,000
+50,000
+14% +$468K
SE icon
68
Sea Limited
SE
$62.9B
$3.84M 0.21%
57,500
– –
NBTX
69
Nanobiotix
NBTX
$1.8B
$3.8M 0.2%
1,000,000
– –
PFTA
70
DELISTED
Perception Capital Corp. III Class A Ordinary Share
PFTA
$3.71M 0.2%
380,000
– –
RXRX icon
71
Recursion Pharmaceuticals
RXRX
$1.74B
$3.66M 0.2%
450,000
– –
RNAM
72
DELISTED
Avidity Biosciences
RNAM
$3.63M 0.19%
250,000
– –
ACIU icon
73
AC Immune
ACIU
$266M
$3.61M 0.19%
1,000,000
– –
DYN icon
74
Dyne Therapeutics
DYN
$3.35B
$3.61M 0.19%
525,000
– –
ADVM
75
DELISTED
Adverum Biotechnologies
ADVM
$3.6M 0.19%
300,000
– –
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q2 2022 Portfolio in Review

As of Q2 2022, Artal Group held 144 positions worth $1.87B, down 22% from $2.39B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Artal Group withdrew a net $95.3M in Q2 2022, closing 9 positions and reducing 8 holdings. Its most notable exit was Protagonist Therapeutics, an estimated $18.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in CinCor Pharma, Inc. Common Stock worth $2.58M.

  • Artal Group's largest Q2 2022 buy was CinCor Pharma, Inc. Common Stock: 137,010 shares worth $2.58M.
  • Artal Group added most to Scholar Rock in Q2 2022, an estimated $45.3M increase.
  • Artal Group's biggest Q2 2022 reduction was argenx, cutting an estimated $60.4M.
  • Artal Group fully exited Protagonist Therapeutics in Q2 2022, selling an estimated $18.9M.
  • Artal Group's ten largest holdings make up 49% of its $1.87B portfolio in Q2 2022.
  • Artal Group opened 7 new positions and closed 9 in Q2 2022.
  • Artal Group's portfolio value fell 22% quarter-over-quarter to $1.87B.

Based on Artal Group's 13F filing for Q2 2022, filed 11 Aug 2022.